GV, Mass General Brigham Ventures and Lonza helped Affinia Therapeutics raise $110m to commercialise work originating at Harvard.
Affinia Therapeutics, a US-based gene therapy developer based on research at Harvard Medical School, completed a $110m series B round on Monday featuring chemicals producer Lonza, internet and technology group Alphabet and healthcare provider Mass General Brigham.
EcoR1 Capital and Farallon Capital Management co-led the round, which included investment and financial services group Fidelity’s F-Prime Capital subsidiary, while Alphabet and Mass General Brigham took part through GV and Mass General Brigham Ventures respectively.
Avidity Partners, Casdin Capital, Octagon…
